Loading stock…

Siemens Healthineers AG (SHL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Siemens Healthineers AG

SHLMarket cap $48BPrice $43.1

Country🇩🇪Germany

SectorHealthcare

IndustryHealthcare Equipment

Makes medical imaging equipment and diagnostics that hospitals worldwide use to scan, diagnose, and treat patients. Installed in over 180 countries, their MRI and CT machines help doctors see inside your body.

In Bastion Portfolios?

52W Return-21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%6

Revenue Forecast

Rev CAGR (1y)-3%2

Rev CAGR (3y)+4%3

Rev CAGR (5y)+5%4

Earnings Forecast

EPS Growth Y+1+21%8

EPS Growth Y+2-1%3

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin14%6

Net Income Margin10%5

Free Cash Flow Margin11%6

Debt

Net Debt/EBITDA3.03

Efficiency

ROE12%5

ROA5%6

Earnings Stability77

GEAR+AVERAGE39

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)145

P/BV2.26

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd156

Yield

Free Cash Flow Yield6.1%7

Dividend Yield2.6%6

Momentum

Short term

1 month return-0%7

3 month return+12%9

YTD return-12%3

Mid term

Price vs 52wHigh79%5

1 year return-19%3

Long term

3 year return-14%2

5 year return-24%2

Risk Shield

Price Risk

Beta1.04

Volatility25%8

Free Cash Flow

Free Cash Flow Margin11%6

Free Cash Flow Yield6.1%7

Quality

ROCE10%6

Earnings Stability77

Net Debt/EBITDA3.03

02Growth

Is it actually growing, and how fast?

SHLSiemens Healthineers

Revenue FY25$27.4B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+21%8

EPS growth, FY27E-1%3

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 1% in year 2.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

SHLSiemens Healthineers

Total return Current11.2%

Price return Current−2.4%

MOMENTUM RATING↗

AVERAGE36 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%7

3-month return+12%9

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return-19%3

3-year return-14%2

5-year return-24%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%) and over three months (+12%).

WATCH

It's down 19% over the past year, now 21% below its 52-week high. That is a touch behind the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -24% over five), behind 80% of the market.

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Siemens Healthineers. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SHLSiemens Healthineers

Revenue FY25$27.4B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+21%8

EPS growth, FY27E-1%3

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 1% in year 2.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

SHLSiemens Healthineers

Total return Current11.2%

Price return Current−2.4%

MOMENTUM RATING↗

AVERAGE36 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%7

3-month return+12%9

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return-19%3

3-year return-14%2

5-year return-24%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%) and over three months (+12%).

WATCH

It's down 19% over the past year, now 21% below its 52-week high. That is a touch behind the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -24% over five), behind 80% of the market.

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Siemens Healthineers. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community